1	The benefit of hypothermic targeted temperature management decreases when
2	post-arrest care improves
3	
4	Wei-Ting Chen, MD ¹ ; Yu-Tzu Tien, MD ¹ ; Chien-Hua Huang, MD, PhD ¹ ; Chih-Hung
5	Wang, MD, PhD ¹ ; Wei-Tien Chang, MD, PhD ¹ ; Hooi-Nee Ong, MD ¹ ; Wen-Jone
6	Chen, MD, PhD ^{1,2,3} ; Min-Shan Tsai, MD, PhD ¹
7	
8	¹ Department of Emergency Medicine, National Taiwan University Medical College
9	and Hospital, Taipei, Taiwan
10	² Department of Internal Medicine (Cardiology division), National Taiwan University
11	Medical College and Hospital, Taipei, Taiwan
12	³ Department of Internal Medicine, Min-Shen General Hospital, Taoyuan, Taiwan
13	
14	Name and address of Corresponding authors:
15	Min-Shan Tsai, MD, PhD
16	Department of Emergency Medicine, National Taiwan University Hospital
17	No. 7, Chung-Shan S. Road, Taipei, Taiwan 100
18	E-mail: mshanmshan@gmail.com
19	
20	The study was performed in National Taiwan University Hospital.
21	
22	Short running title: Less TTM benefit when post-arrest care improves
23	
24	Word count of Abstract: 341 words
25	Word count: 2757 words

1 Abstract

2 Background:

3	Several clinical trials and cohort studies in the past two decades have
4	demonstrated inconsistent results regarding survival and neurologic recovery benefits
5	for patients undergoing targeted temperature management (TTM) at 33°C as
6	compared to those undergoing TTM at 36°C or normothermia. Whether the improved
7	quality of post-arrest care over time contributes to diminishing benefit of TTM at
8	33°C remains un-investigated.
9	Methods:
10	There were 1,809 adult non-traumatic cardiac arrest survivors during 2011-2020.
11	After excluding patients with pre-arrest poor conscious level defined as
12	Glasgow-Pittsburgh Cerebral Performance Category (CPC) >2 (n=258), patients who
13	regained clear consciousness after return of spontaneous circulation (ROSC) (n=300),
14	patients with active bleeding or intracranial hemorrhage (n=48) and patients who
15	underwent TTM of 36°C due to unstable hemodynamic (n=11), a total of 1,192
16	eligible candidates for TTM of 33°C were finally enrolled and classified into Period 1
17	(during 2011-2015, n = 449) and Period 2 (during 2016-2020, n = 693).
18	Results:

19 Patients in Period 2 received more diagnostics procedures and specific therapies

1	than those in Period 1. The proportion of patients with good neurological recovery at
2	hospital discharge in Period 2 is significantly higher than that in Period 1 (21.4%
3	vs.14.0%, adjusted odds ratio [aOR] 1.60, 95% confidence interval [CI] 1.14-2.26).
4	TTM was beneficial for the outcomes in both Period 1 and 2, with patients in Period 1
5	having higher chances of survival and good neurological outcome than those in Period
6	2 (survival: aOR 5.66, 95% CI 3.49-9.18 vs. aOR 2.91, 95% CI 1.98-4.28; good
7	neurological recovery: aOR 3.92, 95% CI 2.12-7.25 vs. aOR 2.19, 95% CI 1.43-3.34).
8	Among patients with low-risk and medium-risk severity of illness, TTM benefited
9	survival and neurological outcomes, regardless of time period. But the chance of
10	beneficial outcomes decreased consistently from Period 1 to Period 2.
10 11	beneficial outcomes decreased consistently from Period 1 to Period 2. Conclusion
11	Conclusion
11 12	Conclusion Among cardiac arrest survivors, improvement in the quality of post-cardiac
11 12 13	Conclusion Among cardiac arrest survivors, improvement in the quality of post-cardiac arrest care over time is associated with better neurological recovery. TTM remains
11 12 13 14	Conclusion Among cardiac arrest survivors, improvement in the quality of post-cardiac arrest care over time is associated with better neurological recovery. TTM remains beneficial for survival and neurological outcomes following cardiac arrest, regardless
11 12 13 14 15	Conclusion Among cardiac arrest survivors, improvement in the quality of post-cardiac arrest care over time is associated with better neurological recovery. TTM remains beneficial for survival and neurological outcomes following cardiac arrest, regardless of the time period. However, the benefit of TTM may diminish when post-cardiac

19 33°C; protocolization

1 Background

2	In recent decade, the dispute whether preventing fever following return of
3	spontaneous circulation (ROSC) rather than reducing body temperature to 33°C was
4	enough to alleviate post-arrest brain injury has been raised, since the TTM and TTM2
5	trials demonstrated no difference in survival and neurological outcomes between
6	patients underwent TTM of 33°C vs. 36°C, ¹ or vs. <37.8°C, ² . However, several
7	retrospective cohort studies have shown less protocol compliance ³ and more fever
8	during the early post-arrest period, ^{3,4} and thus worse survival and neurological
9	recovery in patients underwent targeted temperature management (TTM) of 36°C. ⁴⁻⁶
10	Moreover, the HYPERION trial demonstrated better neurological recovery in TTM of
11	33°C than normothermia among patients with non-shockable rhythm. ⁷ The severity of
12	post-cardiac arrest syndrome was proposed to account for the discrepancies between
13	these studies. Better outcomes were observed when temperature was targeted at 33°C
14	in the patients with moderate-severity. ^{8,9}

In addition to illness severity, the benefit of protocolized post-arrest care in the trials may also attribute to the insignificant difference between hypothermia and normothermia. The importance of post-cardiac arrest care began to be emphasized since 2010, and a multidisciplinary, systemic approach of care was proposed, including optimization of ventilation and hemodynamics, neurologic management,

1	glycemic control, TTM and immediate coronary revascularization. ^{10,11} Our previous
2	study demonstrated that these practices help improve the quality of care in patients
3	without TTM. ¹² However, whether benefit of therapeutic hypothermia over no
4	temperature management decreases along with the improved post-arrest care remains
5	uninvestigated. Before the launch of the 2015 American Heart Association (AHA)
6	guidelines, the National Taiwan University Hospital (NTUH) only used the TTM
7	protocol with a target temperature of 33°C. Since 2016 January, the NTUH protocol
8	has been revised to subject stable patients to TTM at 33°C while only a few patients
9	with unstable hemodynamics or arrhythmia are treated at 36°C. The aim of this study
10	was to examine the benefit of hypothermic TTM at 33°C on survival and favorable
11	neurologic recovery during the time period from 2010 to 2020, in the context of the
12	improvements of post-arrest care.
13	
14	
15	
16	
17	
18	
19	

1 Methods

2 <u>Demographics/Epidemiology</u>

3	This retrospective cohort study was conducted at National Taiwan University
4	Hospital, a 2500-bed tertiary medical center located in Taipei City with 110,000
5	annual emergency department visits ¹³ . The Institutional Review Board of NTUH
6	approved the study(202111079RINA) and waived participant consent.

7 <u>Participants Selection</u>

8 The study enrolled 1,809 adult, non-traumatic cardiac arrest victims with 9 successful resuscitation between January 2011 and December 2020 in the ED of 10 NTUH. Patients were excluded if they had a pre-arrest poor consciousness level, 11 defined as Glasgow-Pittsburgh Cerebral Performance Category (CPC)>2 (n=258), had 12 regained clear consciousness within 3 hours after ROSC (n=300), had massive 13 bleeding or intracranial hemorrhage at ROSC (n=48), and who underwent TTM with 14 a target temperature of 36° C due to unstable hemodynamics (n=11). A total of 1,192 eligible candidates for TTM with target temperature at 33°C were finally enrolled in 15 16 the current study. When further classified by the AHA guidelines revised in Dec 2015, 17 449 patients with an index cardiac arrest between 2011-2015 were further classified as 18 "Period 1", and 693 patients with an index cardiac arrest between 2016-2020 were 19 classified as "Period 2" (Figure 1).

1 <u>TTM Protocol of NTUH</u>

2	NTUH is the first hospital in Taiwan to introduce TTM for cardiac arrest
3	survivors, and has established a protocol for TTM since 2003. After the application of
4	cooling devices was approved by the Taiwan Ministry of Health and Welfare in 2005,
5	the first patient underwent TTM in 2006. The protocols for post-cardiac arrest care,
6	including TTM, were updated sequentially in alignment with the 2010, 2015 and 2020
7	AHA guidelines. ^{10,14,15} Before the launch of 2020 AHA guideline, the cardiac arrest
8	survivors underwent TTM at 33°C except for those with unstable hemodynamic even
9	with more than 2 inotropes support in the early post-arrest period and those with
10	massive bleeding or intracranial hemorrhage after ROSC. Cold saline and cooling
11	devices with auto-feedback were used to reduce patients' body temperatures to the
12	target temperature of 33°C within 4-6 hours after ROSC, maintain target temperature
13	for 24 hours, and rewarm patients at the rate of 0.25°C per hour until 36°C was
14	achieved. Temperature management was continued for another 24 hours after
15	rewarming to avoid fever ¹³ .

16 Data Collection and Variables Definition

17 The primary data set was obtained from the hospital medical record data 18 repository and included demographic information, past medical history, prehospital 19 arrest events, cardiac arrest details, post-arrest management, laboratory examinations,

1 and disposition. This study followed Strengthening the Reporting of Observational

2 Studies in Epidemiology (STROBE) reporting guidelines.¹⁶

3	Patients with cardiac arrest were considered as either those with out-of-hospital
4	cardiac arrest (OHCA), with in-hospital cardiac arrest (IHCA) after triage, or those
5	who achieved ROSC before being transferred from another hospital. Cardiogenic
6	arrest was recorded when ischemic heart disease, structural heart disease, heart failure,
7	or arrhythmia without an electrolyte imbalance was considered the cause of arrest.
8	The causes of cardiac arrest were determined by the responsible primary care
9	physicians, who were blinded to the current study. Repeated CPR was defined as
10	another episode of arrest within one hour after initial ROSC.
11	Overall cardiac arrest severity was assigned using the simplified Cardiac Arrest
12	Hospital Prognosis (sCAHP) score as our previous publication, which excluded the
13	no-flow interval data with similar predictive accuracy as the original score in an East
14	Asian population. ¹⁷ The illness severity (≤150 as low-risk, 151-199 as medium-risk,
15	and ≥ 200 as high-risk) was determined by using the method with a scheme that used
16	significant F-values for cut-off points. ¹⁸ The performance of illness severity
17	categorized by the sCAHP score (our data) and the CAHP score (Sudden Death
18	Expertise Center registry, Paris, France) ¹⁹ is shown in Supplementary Table 1.

During the early post-arrest period, electrocardiogram (ECG), echocardiography

1	and cerebral computed tomography after ROSC were recorded. Emergent coronary
2	angiography (CAG) was recorded when indicated patients underwent CAG within 24
3	hours after ROSC. Extracorporeal membrane oxygenation (ECMO) was recorded
4	when applied as indicated during index resuscitation. Fever (≥38.3°C), infection
5	workup, electroencephalogram (EEG) and anti-epileptic drugs (AED) use during first
6	3 days after ROSC were documented.
7	Outcome Measures
8	The primary outcome was favorable neurological recovery at hospital discharge,
9	defined as a CPC of 1 (good recovery) or 2 (moderate disability). The secondary
10	outcomes include survival at hospital discharge, as well as at 3-month and 1-year
11	follow-ups. CPC at hospital discharge was evaluated by primary care physicians who
12	were blinded to the current study.
13	Patient and public involvement
14	The patients and public were not involved in the creation of the study design,
15	recruitment or statistical analysis. Patients were not consulted to develop patient
16	relevant outcomes or interpret the results. Patients were not invited to contribute to the
17	writing or editing of this manuscript.
18	Statistical Analysis
19	Descriptive statistics were presented as frequencies for categorical variables and

	.1 1'	• . 1	• • 1	C	. •	• • •	D	•
1	the median	with	intermartile	ranges for	continuous	variables	For 2 grou	p comparison,
-	the meanun	** 1011	merquatine	1411505 101	commuous	variables.	10125104	p comparison,

2	Fisher's exact or Pearson's chi-squared test for categorical variables, and the
3	Mann-Whitney U test for continuous variables were used. Multiple imputation
4	(Markov Chain Monte Carlo) was used for missing data of laboratory examinations.
5	Multivariable logistic regression models were used to examine the association
6	between outcomes and time periods, and the benefit of hypothermic TTM over
7	non-TTM on survival and good neurological recovery. All statistical analyses were
8	performed using SPSS Statistics for Windows, version 16.0 (SPSS Inc., Chicago, IL,
9	USA). Statistical significance was assessed using two-sided 95% confidence intervals
10	(CI) and a p<0.05.
11	
12	
13	
14	
15	
16	
17	
18	
19	

- 1
- 2
- 3 **Results**

4 <u>Period 1 vs. Period 2</u>

5 A comparison of the patient characteristics, cardiac arrest events, and laboratory 6 examinations between the two time periods is presented in Table 1. As compared with 7 Period 1, the proportion of coronary artery disease, arrhythmia, OHCA, witnessed 8 collapse, initial shockable rhythm and bystander CPR were higher during Period 2. But 9 the adrenaline dosage, systolic blood pressure at ROSC, PH and HCO₃ of blood gas 10 were lower in patients during Period 2 than Period 1. Patients in Period 2 had higher 11 sCAHP severity and APACHE II scores than those in Period 1. More patients in Period 12 2 received echocardiography, brain CT, emergent CAG, TTM and inotrope support 13 following ROSC as well as EEG and AEDs within 3 days after cardiac arrest. Patients 14 in Period 1 had longer duration from cooling to target temperature and greater highest 15 body temperature when compared with those in Period 2. Increased active withdrawal 16 was also noted in Period 2 (Table 2).

A representation of the proportion of patients that did not survive to hospital
discharge, with poor CPC, and with good CPC between the two time periods can be
seen in Figure 2. Mortality rates are comparable with 71.1% in Period 1 and 72.2% in

1 Period 2. The chance of patients with good neurological recovery at ICU discharge (adjusted OR [aOR] 1.79, 95% CI=1.27-2.51) and hospital discharge (aOR 1.60, 95% 2 3 CI=1.14-2.26) in Period 2 was significantly higher than in Period 1. There were no 4 difference of 3-month and 1-year survival between Period 1 and Period 2 (Table 3). 5 Non-TTM vs. hypothermic TTM 6 There were 374 patients receiving hypothermic TTM following ROSC classified 7 as the TTM group and the rest 818 patients classified as the non-TTM group. A 8 comparison of underlying characteristics, cardiac arrest events, and laboratory results 9 between patients with and without TTM treatment are presented in Supplementary 10 Table 2. The patients in the TTM group were younger than those in the non-TTM group 11 and suffered from less pre-arrest co-morbidity, such as bed-ridden and malignancy. 12 Compared with the non-TTM group, the TTM group had a higher proportion of patients 13 with OHCA, initial shockable rhythm, prehospital CPR, prehospital ROSC and

14 presumed cardiogenic arrest, but less percentage of repeated CPR and high-risk

severity. Besides, the TTM group required a lower adrenaline dosage, and had lower

16 APACHE II scores but higher heart rates, systolic blood pressures, hemoglobin and

17 platelet concentrations than the non-TTM group. Supplementary Table 3 demonstrates

18 better post-arrest care in the TTM group than the non-TTM group including more

19 cardiovascular and cerebral evaluations, better adherence to ventilation and

1	hemodynamic recommendations, more infection workups, and early seizure detection
2	and treatment. A comparison between the TTM and non-TTM groups in each time
3	period is shown in Supplementary Tables 4 and 5.
4	Although significant interaction between time period and TTM was noted, both
5	Period 2 and TTM remained associated with improved neurological recovery
6	(Supplementary Table 6). Compared with the non-TTM group, patients who
7	underwent TTM had better survival (aOR 3.67, 95% CI=2.73-4.93) and neurological
8	outcome (aOR 2.71, 95% CI=1.92-3.82). TTM remained beneficial in both Period 1
9	and Period 2, and the benefit of TTM over non-TTM in survival and neurological
10	recovery was higher in Period 1 as compared to Period 2 (survival: aOR 5.66, 95%
11	CI=3.49-9.18 vs. aOR 2.91, 95% CI=1.98-4.28; good neurological recovery: aOR
12	3.92, 95% CI=2.12-7.25 vs. aOR 2.19, 95% CI=1.43-3.34). The enrolled patients
13	were further stratified by sCAHP severity with 248 patients of low-risk severity, 547
14	patients of medium-risk severity and 397 patients of high-risk severity, respectively.
15	Among patients with low- and medium-risk severity, TTM benefited survival and
16	neurological outcomes, regardless of time period. But the chance for good outcomes
17	consistently decreased from Period 1 to Period 2 in both low- and medium-risk
18	subgroups. There was no significant benefit of TTM in patients with high-risk severity
19	(Figure 3).

1

- 2
- 3
- 4 Discussion

In this study, Period 2 had better post-arrest care than Period 1, and the neurological recovery improved significantly in Period 2. TTM were beneficial for survival and neurological outcomes among cardiac arrest patients in both time periods, especially in those with low- and medium-risk severity; however, its benefit diminished over time.

10 To alleviate post-cardiac arrest syndrome, bundle care focused on identifying the 11 cause of arrest and preventing recurrence, providing ventilation to minimize lung 12 injury, optimizing cardiovascular function, early detecting and treating post-arrest 13 seizure, reducing risk of multiorgan injury, and controlling body temperature has been suggested by AHA guidelines since 2010.¹⁰ In the current study, patients in Period 2 14 15 had increased diagnostics procedures performed and specific therapies given for 16 timely and appropriate management than those in Period 1. Although both short-term 17 and long-term survival are comparable between Period 1 and Period 2, the benefit of 18 improved post-cardiac arrest care might be reflected in more favorable neurological 19 recovery in Period 2. The increased active withdrawal for patients with potentially 20 poor neurological outcome and "do-not-attempt resuscitation" after ROSC in Period 2 21 may account for the insignificant difference in survival at hospital discharge between

1	these 2 periods. Besides, the finding that approximately half of the patients discharged
2	from the hospital died within 3 months emphasizes the importance of rehabilitation
3	and health care after hospital discharge. Further studies are warrant to investigate the
4	causes of death after hospital discharge.
5	In our current study, TTM at 33°C remains beneficial in both time periods. The
6	benefits of hypothermic TTM over non-TTM decreased in Period 2 in all enrolled
7	patients as well as subgroups stratified by illness severity. The improved post-arrest
8	care may account for this finding since the interventions were in place for all
9	successfully resuscitated victims, regardless of TTM treatments. This finding also
10	raises another important question-Does the benefit of TTM on outcomes truly result
11	from TTM or the protocolized care established along with TTM? Laboratory animal
12	studies displayed that therapeutic hypothermia at 32-33 °C ameliorated myocardial
13	injury and brain damage after ischaemia/reperfusion injury, and thus, improved
14	survival and neurological recovery. ^{20,21} However, clinical trials showed inconsistent
15	results concerning the benefit of TTM at 33 °C as compared with normothermia or no
16	temperature control. ^{1,2,7,22,23}

Bernard et al. , HACA and HYPERION trials demonstrated improved survival
and neurological outcomes in patients underwent therapeutic hypothermia at 33
°C.^{7,22,23} However, the TTM trial demonstrated no difference in survival and

1	neurological recovery between patients receiving TTM at 33 °C and 36 °C,
2	emphasizing the importance of temperature control rather than the low target
3	temperature. ¹ In 2021, the TTM2 trial once again demonstrated no outcome benefit in
4	patients receiving TTM at 33 °C compared with those <37.8 °C, implying that
5	aggressively preventing fever may be the main determinant factor. ² The evolution of
6	post-cardiac arrest care within the two decades may account for the inconsistent
7	results of these trials. Similar situation can be observed in the care of sepsis. The
8	ARISE trial failed to show the benefit of early goal-directed therapy(EGDT) in
9	reducing mortality, and the improvement of medical care quality along with the
10	protocol establishment was proposed as a reason for comparable outcomes in the
11	EGDT and control groups. ²⁴ The protocolized approaches usually facilitate medical
12	teams to provide more consistent care and overcome barriers. ^{25,26} Our results supported
13	the hypothesis that the improved quality of post-arrest care would diminish the benefit
14	of TTM on outcomes. Several retrospective cohort studies also demonstrated worse
15	outcomes in patients with less adherence to protocols of temperature control. ³⁻⁵
16	Similar diminished difference between intervention and standard groups can also be
17	observed in the Box trial: no outcome difference between different blood-pressure
18	targets and different oxygen targets in cardiac arrest survivors. ^{27,28}

19 Limitation

1	This study had several limitations. First, due to the its retrospective nature,
2	selection bias was unavoidable, and unidentified confounding factors or improvement
3	of post-arrest care might be present. Second, the post-cardiac arrest care in the TTM
4	group were better than that in the non-TTM group. The frequency of CT, emergent
5	CAG and EEG of the TTM group were comparable with those in published
6	studies. ^{2,5,9} However, there is a lack of studies reporting the quality of post-arrest care
7	in patients without TTM and we cannot compare our results with others. Nevertheless,
8	our results indicated that much room for us to improve the care quality in patients
9	without TTM. And the care discrepancy between the TTM and non-TTM groups
10	might be the primary source of the TTM benefit as we hypothesized. Third, the
11	reasons for patients not undergoing TTM were not recorded. The socioeconomic status
12	of these patients, which might affect willingness to undergo TTM, was also not
13	considered. However, standard ICU and post-arrest care are covered by National Health
14	Insurance in Taiwan, and TTM was incorporated into the coverage in October 2015.
15	Additionally, the neurological function was not recorded during the follow-up after
16	hospital discharge. Finally, our study investigated a homogenous Asian population,
17	and great caution should be exercised when attempting to extrapolate our results to
18	other races.

1 Conclusion

2	Among cardiac arrest survivors, the improved quality of post-cardiac arrest care
3	over time is associated with better neurological recovery. Regardless of the time
4	periods, hypothermic TTM remained beneficial to survival and neurological outcomes
5	following cardiac arrest. However, benefit of TTM over non-TTM might be
6	diminished along with improvement in post-cardiac arrest care.
7	
8	Declarations
9	Ethics approval and consent to participate:
10	This retrospective cohort study was approved by the Institutional Review Board
11	of NTUH (202111079RINA) and waived participant consent.
12	Consent for publication: not applicable
13	Availability of data and material:
14	The data sets used and analysed during the current study are available from the
15	corresponding author on reasonable request
16	Competing interests: The authors declare that they have no competing interests.
17	<u>Funding</u> : not applicable
18	Authors' contributions:
19	All authors contributed to the study conception and design. Material

- 1 preparation and data collection were performed by CWT and OHN. The
- 2 analysis was performed by TMS, TYT and WCH. The first draft of the
- 3 manuscript was written by CWT. TMS, HCH and CWJ revised it critically for
- 4 important intellectual content.
- 5 Acknowledgements
- 6 The authors would like to express their thanks to the staff of National Taiwan
- 7 University Hospital-Statistical Consulting Unit (NTUH-SCU) for statistical
- 8 consultation.
- 9

1 References

2	1.	Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J,
3		Hovdenes J, Kjaergaard J, Kuiper M, et al. Targeted temperature management
4		at 33 degrees C versus 36 degrees C after cardiac arrest. N Engl J Med.
5		2013;369:2197-2206. doi: 10.1056/NEJMoa1310519
6	2.	Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullen S, Rylander C,
7		Wise MP, Oddo M, Cariou A, et al. Hypothermia versus Normothermia after
8		Out-of-Hospital Cardiac Arrest. N Engl J Med. 2021;384:2283-2294. doi:
9		10.1056/NEJMoa2100591
10	3.	Bray JE, Stub D, Bloom JE, Segan L, Mitra B, Smith K, Finn J, Bernard S.
11		Changing target temperature from 33 degrees C to 36 degrees C in the ICU
12		management of out-of-hospital cardiac arrest: A before and after study.
13		Resuscitation. 2017;113:39-43. doi: 10.1016/j.resuscitation.2017.01.016
14	4.	Salter R, Bailey M, Bellomo R, Eastwood G, Goodwin A, Nielsen N, Pilcher D,
15		Nichol A, Saxena M, Shehabi Y, et al. Changes in Temperature Management of
16		Cardiac Arrest Patients Following Publication of the Target Temperature
17		Management Trial. Crit Care Med. 2018;46:1722-1730. doi:
18		10.1097/CCM.000000000003339
19	5.	Johnson NJ, Danielson KR, Counts CR, Ruark K, Scruggs S, Hough CL, Maynard
20		C, Sayre MR, Carlbom DJ. Targeted Temperature Management at 33 Versus 36
21		Degrees: A Retrospective Cohort Study. Crit Care Med. 2020;48:362-369. doi:
22		10.1097/CCM.000000000004159
23	6.	Minini A, Annoni F, Peluso L, Bogossian EG, Creteur J, Taccone FS. Which
24		Target Temperature for Post-Anoxic Brain Injury? A Systematic Review from
25		"Real Life" Studies. Brain Sci. 2021;11. doi: 10.3390/brainsci11020186
26	7.	Lascarrou JB, Merdji H, Le Gouge A, Colin G, Grillet G, Girardie P, Coupez E,
27		Dequin PF, Cariou A, Boulain T, et al. Targeted Temperature Management for
28		Cardiac Arrest with Nonshockable Rhythm. N Engl J Med.
29		2019;381:2327-2337. doi: 10.1056/NEJMoa1906661
30	8.	Callaway CW, Coppler PJ, Faro J, Puyana JS, Solanki P, Dezfulian C, Doshi AA,
31		Elmer J, Frisch A, Guyette FX, et al. Association of Initial Illness Severity and
32		Outcomes After Cardiac Arrest With Targeted Temperature Management at
33		36 degrees C or 33 degrees C. JAMA Netw Open. 2020;3:e208215. doi:
34		10.1001/jamanetworkopen.2020.8215
35	9.	Nishikimi M, Ogura T, Nishida K, Hayashida K, Emoto R, Matsui S, Matsuda N,
36		Iwami T. Outcome Related to Level of Targeted Temperature Management in
37		Postcardiac Arrest Syndrome of Low, Moderate, and High Severities: A

1		Nationwide Multicenter Prospective Registry. Crit Care Med.
2		2021;49:e741-e750. doi: 10.1097/CCM.0000000000005025
3	10.	Peberdy MA, Callaway CW, Neumar RW, Geocadin RG, Zimmerman JL,
4		Donnino M, Gabrielli A, Silvers SM, Zaritsky AL, Merchant R, et al. Part 9:
5		post-cardiac arrest care: 2010 American Heart Association Guidelines for
6		Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
7		<i>Circulation</i> . 2010;122:S768-786. doi: 10.1161/circulationaha.110.971002
8	11.	Chen WT, Tsai MS, Huang CH, Chang WT, Chen WJ. Protocolized Post-Cardiac
9		Arrest Care with Targeted Temperature Management. Acta Cardiol Sin.
10		2022;38:391-399. doi: 10.6515/ACS.202205_38(3).20211220A
11	12.	Ling DA HC, Chen WJ, Chuang PY, Chang WT, Sung CW, Chen WT, Ong HN, Tsai
12		MS. Impact of protocolized postarrest care with targeted temperature
13		management on the outcomes of cardiac arrest survivors without
14		temperature management. Ann Med. 2022;54:63-70.
15	13.	Lin JJ, Huang CH, Chen WJ, Chuang PY, Chang WT, Chen WT, Tsai MS. Targeted
16		temperature management and emergent coronary angiography are
17		associated with improved outcomes in patients with prehospital return of
18		spontaneous circulation. J Formos Med Assoc. 2020;119:1259-1266. doi:
19		10.1016/j.jfma.2020.03.017
20	14.	Neumar RW, Shuster M, Callaway CW, Gent LM, Atkins DL, Bhanji F, Brooks SC,
21		de Caen AR, Donnino MW, Ferrer JM, et al. Part 1: Executive Summary: 2015
22		American Heart Association Guidelines Update for Cardiopulmonary
23		Resuscitation and Emergency Cardiovascular Care. Circulation.
24		2015;132:S315-367. doi: 10.1161/CIR.000000000000252
25	15.	Panchal AR, Bartos JA, Cabañas JG, Donnino MW, Drennan IR, Hirsch KG,
26		Kudenchuk PJ, Kurz MC, Lavonas EJ, Morley PT, et al. Part 3: Adult Basic and
27		Advanced Life Support: 2020 American Heart Association Guidelines for
28		Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
29		Circulation. 2020;142:S366-s468. doi: 10.1161/cir.000000000000916
30	16.	Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ,
31		Poole C, Schlesselman JJ, Egger M, Initiative S. Strengthening the Reporting of
32		Observational Studies in Epidemiology (STROBE): explanation and elaboration.
33		International journal of surgery. 2014;12:1500-1524. doi:
34		10.1016/j.ijsu.2014.07.014
35	17.	Wang CH, Huang CH, Chang WT, Tsai MS, Yu PH, Wu YW, Chen WJ. Prognostic
36		performance of simplified out-of-hospital cardiac arrest (OHCA) and cardiac
37		arrest hospital prognosis (CAHP) scores in an East Asian population: A
38		prospective cohort study. Resuscitation. 2019;137:133-139. doi:

4		
1	10	10.1016/j.resuscitation.2019.02.015
2	18.	Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer
3		pain mild, moderate or severe? Grading pain severity by its interference with
4	10	function. Pain. 1995;61:277-284. doi: 10.1016/0304-3959(94)00178-H
5	19.	Maupain C, Bougouin W, Lamhaut L, Deye N, Diehl JL, Geri G, Perier MC,
6		Beganton F, Marijon E, Jouven X, et al. The CAHP (Cardiac Arrest Hospital
7		Prognosis) score: a tool for risk stratification after out-of-hospital cardiac
8		arrest. Eur Heart J. 2016;37:3222-3228. doi: 10.1093/eurheartj/ehv556
9	20.	Tsai MS, Huang CH, Tsai CY, Chen HW, Cheng HJ, Hsu CY, Chang WT, Chen WJ.
10		Combination of intravenous ascorbic acid administration and hypothermia
11		after resuscitation improves myocardial function and survival in a ventricular
12		fibrillation cardiac arrest model in the rat. Acad Emerg Med. 2014;21:257-265.
13		doi: 10.1111/acem.12335
14	21.	Huang CH, Tsai MS, Chiang CY, Su YJ, Wang TD, Chang WT, Chen HW, Chen WJ.
15		Activation of mitochondrial STAT-3 and reduced mitochondria damage during
16		hypothermia treatment for post-cardiac arrest myocardial dysfunction. Basic
17		Res Cardiol. 2015;110:59. doi: 10.1007/s00395-015-0516-3
18	22.	Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K.
19		Treatment of comatose survivors of out-of-hospital cardiac arrest with
20		induced hypothermia. N Engl J Med. 2002;346:557-563. doi:
21		10.1056/NEJMoa003289
22	23.	Group HaCAS. Mild therapeutic hypothermia to improve the neurologic
23		outcome after cardiac arrest. New England Journal of Medicine.
24		2002;346:549-556.
25	24.	Investigators A, Group ACT, Peake SL, Delaney A, Bailey M, Bellomo R,
26		Cameron PA, Cooper DJ, Higgins AM, Holdgate A, et al. Goal-directed
27		resuscitation for patients with early septic shock. N Engl J Med.
28		2014;371:1496-1506. doi: 10.1056/NEJMoa1404380
29	25.	Weng TI, Huang CH, Ma MH, Chang WT, Liu SC, Wang TD, Chen WJ. Improving
30		the rate of return of spontaneous circulation for out-of-hospital cardiac
31		arrests with a formal, structured emergency resuscitation team. Resuscitation.
32		2004;60:137-142. doi: 10.1016/j.resuscitation.2003.09.007
33	26.	Galpern D, Guerrero A, Tu A, Fahoum B, Wise L. Effectiveness of a central line
34		bundle campaign on line-associated infections in the intensive care unit.
35		Surgery. 2008;144:492-495; discussion 495. doi: 10.1016/j.surg.2008.06.004
36	27.	Kjaergaard J, Moller JE, Schmidt H, Grand J, Molstrom S, Borregaard B, Veno S,
37		Sarkisian L, Mamaev D, Jensen LO, et al. Blood-Pressure Targets in Comatose
38		Survivors of Cardiac Arrest. N Engl J Med. 2022;387:1456-1466. doi:

- 1 10.1056/NEJMoa2208687
- 2 28. Schmidt H, Kjaergaard J, Hassager C, Molstrom S, Grand J, Borregaard B,
- 3 Roelsgaard Obling LE, Veno S, Sarkisian L, Mamaev D, et al. Oxygen Targets in
- 4 Comatose Survivors of Cardiac Arrest. *N Engl J Med*. 2022;387:1467-1476. doi:
- 5 10.1056/NEJMoa2208686
- 6

Table 1. Comparison of patient characteristics between time periods

	Overall	Period 1 2011-2015	Period 2 2016-2020	p-value
	n = 1192	n = 499	n = 693	
Male Sex (%)	802 (67.3)	325 (65.1)	477 (68.8)	0.189
Age, median(IQR), yr	68 (56-79)	67 (55-79)	68 (57-79)	0.290
Age ≥65 yrs (%)	693 (58.1)	276 (55.3)	417 (60.2)	0.096
Underlying Characteristics				
Hypertension (%)	622 (52.2)	244 (48.9)	378 (54.5)	0.060
Diabetes mellitus (%)	365 (30.6)	155 (31.1)	210 (30.3)	0.799
Hyperlipidemia (%)	112 (9.4)	37 (7.4)	75 (10.8)	0.056
CAD (%)	346 (29.0)	123 (24.6)	223 (32.2)	0.005
Heart failure (%)	118 (9.9)	44 (8.8)	74 (10.7)	0.326
VHD (%)	28 (2.3)	8 (1.6)	20 (2.9)	0.177
Arrhythmia (%)	141 (11.8)	48 (9.6)	93 (13.4)	0.046
COPD/Asthma (%)	100 (8.4)	43 (8.6)	57 (8.2)	0.833
Renal disease (%)	116 (9.7)	53 (10.6)	63 (9.1)	0.428
ESRD (%)	107 (9.0)	40 (8.0)	67 (9.7)	0.356
CVA (%)	104 (8.7)	37 (7.4)	67 (9.7)	0.178
Dementia (%)	50 (4.2)	25 (5.0)	25 (3.6)	0.244
Bedridden (%)	49 (4.1)	14 (2.8)	35 (5.1)	0.056
Malignancy (%)	289 (24.2)	122 (24.4)	167 (24.1)	0.891
Cardiac Arrest Events				
Source (%)				
OHCA	736 (61.7)	285 (57.1)	451 (65.1)	0.017
IHCA	386 (32.4)	179 (35.9)	207 (29.9)	
Transfer	70 (5.9)	35 (7.0)	35 (5.1)	
Witnessed collapse (%)	969 (81.3)	391 (78.4)	578 (83.4)	0.029
Initial shockable rhythm (%)	289 (24.2)	99 (19.8)	190 (27.4)	0.003
Bystander CPR (%)	667 (56.0)	246 (49.3)	421 (60.8)	< 0.00
Prehospital ROSC (%)	106 (9.6)	39 (8.8)	67 (10.0)	0.533
Adrenaline ≥3 mg (%)	607 (50.9)	275 (55.1)	332 (47.9)	0.016
CPR duration, median(IQR), min	19 (9-33)	18 (9-30)	20 (9-34)	0.129
CPR ≤10 min (%)	338 (29.0)	142 (29.6)	196 (28.6)	0.331
CPR 10-20 min (%)	251 (21.5)	112 (23.3)	139 (20.3)	
CPR ≥20 min (%)	576 (49.4)	226 (47.1)	350 (51.1)	
Cardiogenic arrest (%)	591 (49.6)	239 (47.9)	352 (50.8)	0.348
Repeated CPR (%)	409 (34.3)	161 (32.3)	248 (35.8)	0.216
ROSC HR, median(IQR), bpm	105 (79-128)	107 (79-129)	104 (79-129)	0.573
ROSC SBP, median(IQR), mmHg	117 (86-152)	121 (90-159)	116 (85-151)	0.039
sCAHP severity (%)		×/	()	

248 (20.8)	105 (21.0)	143 (20.6)	0.002
547 (45.9)	255 (51.1)	292 (42.1)	_
397 (33.3)	139 (27.9)	258 (37.2)	_
32 (26-37)	28 (24-33)	34 (30-39)	< 0.001
12.02 (8.94-16.36)	12.28 (9.06-16.69)	11.84 (8.85-16.18)	0.353
12.3 (10.0-14.6)	12.1 (10.0-14.4)	12.5 (10.0-14.7)	0.284
190 (139-252)	187 (134-244)	194 (142-257)	0.157
9.7 (6.5-13.0)	9.3 (6.1-12.7)	9.9 (6.7-13.2)	0.122
7.11 (6.99-7.23)	7.14 (7.05-7.24)	7.08 (6.95-7.21)	< 0.001
19.0 (15.0-23.6)	19.7 (15.7-24.9)	18.5 (14.6-22.9)	< 0.001
	547 (45.9) 397 (33.3) 32 (26-37) 12.02 (8.94-16.36) 12.3 (10.0-14.6) 190 (139-252) 9.7 (6.5-13.0) 7.11 (6.99-7.23)	547 (45.9) 255 (51.1) 397 (33.3) 139 (27.9) 32 (26-37) 28 (24-33) 12.02 12.28 (8.94-16.36) (9.06-16.69) 12.3 (10.0-14.6) 12.1 (10.0-14.4) 190 (139-252) 187 (134-244) 9.7 (6.5-13.0) 9.3 (6.1-12.7) 7.11 (6.99-7.23) 7.14 (7.05-7.24)	547 (45.9) 255 (51.1) 292 (42.1) 397 (33.3) 139 (27.9) 258 (37.2) 32 (26-37) 28 (24-33) 34 (30-39) 12.02 12.28 11.84 (8.94-16.36) (9.06-16.69) (8.85-16.18) 12.3 (10.0-14.6) 12.1 (10.0-14.4) 12.5 (10.0-14.7) 190 (139-252) 187 (134-244) 194 (142-257) 9.7 (6.5-13.0) 9.3 (6.1-12.7) 9.9 (6.7-13.2) 7.11 (6.99-7.23) 7.14 (7.05-7.24) 7.08 (6.95-7.21)

Data presented as no. (%) or as median (IQR).

CAD, coronary artery disease; CPR, cardiopulmonary resuscitation; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; ESRD, end-stage renal disease; HR, heart rate; IHCA, in-hospital cardiac arrest; OHCA, out-of-hospital cardiac arrest; ROSC, return of spontaneous circulation; SBP, systolic blood pressure; sCAHP, simplified Cardiac Arrest Hospital Prognosis; VHD, valvular heart disease.

·	Overall	Period 1 2011-2015	Period 2 2016-2020	p-value
	n = 1192	n = 499 (41.9%)	n = 693 (58.1%)	1
ECG after ROSC (%)	1111 (93.2)	458 (91.8)	653 (94.2)	0.103
Echocardiography after ROSC (%)	583 (48.9)	227 (45.5)	356 (51.4)	0.046
Brain CT after ROSC (%)	782 (65.6)	279 (55.9)	503 (72.6)	< 0.001
Emergent CAG (%)	250 (21.0)	85 (17.0)	165 (23.5)	0.005
TTM of 33°C (%)	374 (31.4)	142 (28.5)	232 (33.5)	0.067
ROSC to start cooling, median(IQR), hr	4 (2-6)	3 (2-6)	4 (2-6)	0.514
Cooling to target temperature, median(IQR), hr	4 (2-7)	5 (3-9)	3 (2-6)	< 0.001
Rewarming duration, median(IQR), hr	14 (12-19)	15 (11-21)	14 (12-18)	0.152
ECMO (%)	226 (19.0)	93 (18.6)	133 (19.2)	0.823
ROSC 3hr				
MAP≥65 mmHg (%)	749 (83.8)	290 (82.4)	459 (84.7)	0.403
inotrope use (%)	751 (63.0)	293 (58.7)	458 (66.1)	0.011
PO2 75-100 mmHg (%)	138 (11.6)	59 (11.8)	79 (11.4)	0.855
PCO2 35-45 mmHg (%)	246 (25.9)	91 (23.5)	155 (27.5)	0.176
Lactic acid change from ROSC, median(IQR), mmol/L	-0.90 (-6.08-5.20)	-0.16 (-5.07-5.46)	-1.64 (-6.33-4.45)	0.067
Decreased Lactic acid from ROSC (%)	264 (55.7)	119 (51.1)	145 (60.2)	0.052
Within 3 days after ROSC				
Fever(≥38.3°C) (%)	208 (17.4)	97 (19.4)	111 (16.0)	0.142
Highest body temperature , median(IQR), °C	37.1 (36.0-38.0)	37.3 (36.0-38.1)	37.0 (36.0-37.9)	0.030
Infection workup (%)	742 (63.0)	297 (61.2)	445 (64.1)	0.327
EEG (%)	223 (18.7)	71 (14.2)	152 (21.9)	0.001
AED use (%)	227 (19.0)	68 (13.6)	159 (22.9)	< 0.001

Table 2. Comparison of post-arrest care between time periods

Data presented as no. (%) or as median (IQR).

AED, anti-epileptic drugs; CAG, coronary angiography; CT, computed tomography; ECG, electrocardiogram; ECMO, extracorporeal myocardial oxygenation; EEG,

electroencephalogram; MAP, mean arterial pressure; ROSC, return of spontaneous circulation; TTM, targeted temperature management.

Table 3. Comparison of outcomes between time periods

	Overall	Period 1 2011-2015	Period 2 2016-2020	OR (95% CI)	aOR† (95% CI)
	n = 1192	n = 499	n = 693		
Active withdrawal (%)	117 (9.8)	34 (6.8)	83 (12.0)	1.86 (1.23-2.83)*	1.84 (1.19-2.83)*
Survival to ICU discharge (%)	386 (32.4)	162 (32.5)	224 (32.3)	0.99 (0.77-1.27)	0.88 (0.67-1.15)
Favorable outcome at ICU discharge (%)	222 (18.6)	66 (13.2)	156 (22.5)	1.91 (1.39-2.61)‡	1.79 (1.27-2.51)*
Survival to hospital discharge (%)	337 (28.3)	144 (28.9)	193 (27.8)	0.95 (0.74-1.23)	0.83 (0.62-1.09)
Favorable outcome at hospital discharge (%)	218 (18.3)	70 (14.0)	148 (21.4)	1.66 (1.22-2.27)*	1.60 (1.14-2.26)*
Cardiac cause of death (%)	286 (24.0)	116 (23.2)	170 (24.5)	1.07 (0.82-1.31)	1.05 (0.79-1.39)
3-month survival (%)	182 (15.3)	75 (15.0)	107 (15.4)	1.03 (0.75-1.42)	0.92 (0.64-1.31)
1-year survival (%)	169 (14.2)	70 (14.0)	99 (14.3)	1.02 (0.73-1.42)	0.87 (0.61-1.26)

Period 1 as reference group, CPC=1-2 was considered favorable neurological outcome

Data presented as no. (%)

[†] adjusted by age, initial shockable rhythm, witnessed collapse, and CPR duration groups *p <0.05, ±p<0.001

aOR, adjusted odds ratio; CI, confidence interval; CPC, cerebral performance category; ICU, intensive care unit.

Figure Legends

Figure 1. The flowchart of enrolled patients

CPC, Glasgow-Pittsburgh Cerebral Performance Category; ICH, intracranial hemorrhage; ROSC, return of spontaneous circulation; TTM, targeted temperature management.

Figure 2. Comparison of Outcomes between Time Periods

CPC, Glasgow-Pittsburgh Cerebral Performance Category


Figure 3. The benefit of TTM over non-TTM in survival and neurological outcomes

Non-TTM as reference group, CPC=1-2 was considered as favorable neurological recovery


† adjusted by age, initial shockable rhythm, witnessed collapse, and CPR duration groups

aOR, adjusted odds ratio; CI, confidence interval; CPC, cerebral performance

category; TTM, targeted temperature management




Comparison of Outcomes between Time Periods




(A) Survival

	Non-TTM	TTM	aOR [↑]
Total patients			
overall	158/818(19.3%)	179/374(47.9%)	3.67
period I	64/357(17.9%)	80/142(56.3%)	5.66
period II	94/461(20.4%)	99/232(42.7%)	2.91
Low risk			
overall	47/147(32.0%)	78/101(77.2%)	4.87
period I	18/68(26.5%)	34/37(91.9%)	16.57
period II	29/79(36.7%)	44/64(68.8%)	3.33
Median risk			
overall	78/383(20.4%)	77/164(47.0%)	3.64
period I	34/185(18.4%)	37/70(52.9%)	5.08
period II	44/198(22.2%)	40/94(42.6%)	2.82
High risk			
overall	33/288(11.5%)	24/109(22.0%)	1.70
period I	12/104(11.5%)	9/35(25.7%)	1.81
period II	21/184(11.4%)	15/74(20.3%)	1.65



(B) Favorable neurological recovery

т	Non-TTM
114/37	104/818(12.7%)
42/14	28/357(7.8%)
72/23	76/461(16.5%)
62/10	39/147(26.5%)
25/3	13/68(19.1%)
37/6	26/79(32.9%)
43/16	50/383(13.1%)
15/7	13/185(7.0%)
28/9	37/198(18.7%)
9/1	15/288(5.2%)
2	2/104(1.9%)
7	13/184(7.1%)



Favor non-TTM

Favor TTM